Videos

Karen Reckamp, MD, reviews recent therapeutic findings and the treatment spectrum for ALK+ NSCLC, as well as her clinical experience in using some of these treatments.

Karen Reckamp, MD, provides an overview of the case of a 68-year-old woman with ALK+ NSCLC, including the initial presentation, clinical work-up, treatment, and the importance of molecular testing.

Matthew Lunning, DO, presents a case of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma and discusses considerations for therapy.

Matthew Lunning, DO, presents a case study of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma.

Karen Reckamp, MD, comments on the management and treatment of a 68-year-old woman with ALK+ NSCLC, as well as data demonstrated in the ALTA-1L trial, use of brigatinib, and her own clinical experiences.

Managing patients with who progress on a TKI, the role of re-biopsy at progression of disease, and the future treatment landscape for ALK+ mNSCLC.

A review of the open-label, phase 3 ALTA-1L trial comparing the use of brigatinib to crizotinib in ALK+ metastatic non-small-cell lung cancer.

Approaching TKI (tyrosine kinase inhibitor)-based therapy for the first-line management of ALK+ mNSCLC.

Joshua M. Bauml, MD, presents the case of a 57-year-old man with ALK fusion+ non-small-cell lung cancer (NSCLC) and discusses recommended molecular tests to identify patients with molecular driver alterations.

Joshua M. Bauml, MD, provides insight on the treatment of ALK fusion+ non-small cell lung cancer with tyrosine kinase inhibitors.

Sara A. Hurvitz, MD, discusses sequencing the current therapies for patients with HER2-positive breast cancer.

An expert in ovarian cancer considers the future of ovarian cancer treatment, the use of PARP inhibitors and overcoming PARP resistance, and the emerging treatments options.

Erin Crane, MD, discusses the role of PARP inhibitors in the treatment of ovarian cancer.

Erin Crane, MD, provides an overview of the Phase 3 NOVA trial.

Erin Crane, MD, reviews second- and third-line treatment options and the impact of platinum sensitivity on treatment selection.

An expert in ovarian cancer discusses the role of molecular testing in ovarian cancer and the benefits of incorporating systemic frontline therapy into treatment plans.

Erin Crane, MD, provides an overview of a 63-year-old female patient diagnosed with recurrent ovarian cancer, discussing the initial presentation, clinical work-up, treatment, and her initial impression of the case.

Erin Crane, MD, reviews the case of a 63-year-old woman with recurrent ovarian cancer and discusses treatment options, the Phase 3 NOVA trial, and the future of ovarian cancer treatment.

An expert in multiple myeloma provides clinical pearls for disease management from initial diagnosis through multiple lines of therapy.

Dr. Natalie Callander describes promising new treatment approaches for patients with multiple myeloma.

An expert in multiple myeloma talks through the considerations for treatment selection in the third line for patient with multiple myeloma.

Dr. Natalie Callander provides insight on selection of second-line therapy after transplant patients with multiple myeloma.

Natalie Callander, MD, presents a case of a 68-year-old man with multiple myeloma and reviews first-line treatment options.

Natalie Callander, MD, presents a case of a 68-year-old man with multiple myeloma.

Adriana Rossi, MD, provides clinical pearls on the management of triple-class refractory multiple myeloma.

An expert in multiple myeloma shares her perspective on the significance of recent single-agent approvals for patients with triple-class refractory multiple myeloma and highlights promising combination regimens under investigation.

Dr Adrianna Rossi reviews considerations for treatment selection in the triple-class refractory setting in patients with multiple myeloma.

Adriana Rossi, MD, describes key clinical trials and their implications for the management of triple-class refractory multiple myeloma.

Dr Adriana Rossi reviews the therapeutic options for patients with triple-class refractory multiple myeloma in terms of mechanism of action and safety profile.

An expert in multiple myeloma provides insight on the treatment challenges for patients with triple-class refractory disease, particularly after fourth or later lines.